Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity, catalytic domains, and cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains, and cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains, or cellulose binding domains.

Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.

Abstract: Provided are isolated polypeptides having endoglucanase activity, catalytic domains, carbohydrate binding modules and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding modules. Also provided are nucleic acid constructs, vectors and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding modules.

Abstract: Disclosed are mammalian tau proteases, as well as proteolytically-active fragments, variants, and mutants thereof. Also disclosed are polynucleotides and recombinant expression vectors that encode these polypeptides, as well as methods for producing such proteins in selected recombinant host cells, and for using the compositions in a variety of diagnostic and analytical assays.

Abstract: The present invention relates to a modified and optimized Factor VIII or Factor IX nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia.

Abstract: An optimized multi-step cell line screening method based on next generation sequencing (NGS) and mass spec (MS) is disclosed. The method helps reduce variants in the biologic-producing cell line and improve the efficiency of cell line development process.

Abstract: Using a biopanning method, a heat-stable antibody-displayed phage is acquired. More particularly, first, an antibody-displayed phage library aqueous solution containing plural types of antibody-displayed phages is supplied to a support comprising a polypeptide on the surface thereof, so as to bind the plural types of the antibody-displayed phages to the polypeptide specifically. Next, the support is heated to the temperature of not less than 37 degrees Celsius and not more than 70 degrees Celsius, so as to release a portion of the antibody-displayed phages from the support and so as to leave the other antibody-displayed phages on the support selectively. Finally, the other antibody-displayed phages which has been left on the support selectively in the previous step is collected to obtain the heat-stable antibody-displayed phage.

Abstract: Provided herein is a method of reducing adapter dimer formation comprising contacting a sample comprising target nucleic acid sequences with 5? and 3? adapters in the presence of one or more hairpin oligonucleotides. Also provided is a method of preparing a library of nucleic acid sequences comprising contacting first adapter oligonucleotides with a sample comprising target nucleic acid sequences under conditions to form first ligation products, contacting the sample with one or more hairpin oligonucleotides that binds to the first adapter oligonucleotides, and contacting the sample with second adapter oligonucleotides under conditions to bind to the first ligation products and form second ligation products, wherein the second ligation products form the library of nucleic acid sequences.

Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.

Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.

Abstract: Improved compositions and methods for treating muscular dystrophy by administering antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping are described.

Abstract: The invention pertains to modifications for antisense oligonucleotides, wherein the modifications are used to improve stability and provide protection from nuclease degradation. The modifications could also be incorporated into double-stranded nucleic acids, such as synthetic siRNAs and miRNAs.

Abstract: The disclosure relates to oligonucleotide compounds (oligomers) that target Myc mRNA in a cell, leading to reduced expression of Myc. Reduction of Myc expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The disclosure provides therapeutic compositions comprising oligomers and methods for modulating the expression of Myc using said oligomers, including methods of treatment.

Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.

Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.

Abstract: The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections.

Abstract: The present invention relates to compositions and methods for delivery of siRNA to specific cells or tissue. More particularly, the present invention relates to compositions and methods for cell type-specific delivery of anti-HIV siRNAs via fusion to an anti-gp120 aptamer.

Abstract: MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers.

Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases and colon diseases.

Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.

Abstract: This application describes methods and compositions for reducing, inhibiting and/or treating pain that involve use of ERK2 inhibitors.

Abstract: Methods of inhibiting lymphangiogenesis and/or angiogenesis in a subject are provided. In one aspect, for example, a method of inhibiting angiogenesis in a subject can include binding an antisense morpholino to an mRNA splicing site of VEGFR1 selected from exon13_intron13 junction, intron13_exon14 junction, or a combination thereof. In another aspect, the morpholino includes a member selected from VEGFR1_MOe13, VEGFR1_MOi13, or a combination thereof.

Abstract: The present invention provides an aptamer binding to midkine and capable of forming a potential secondary structure represented by the formula (I): wherein X1, X2, X5 and X6 are the same or different and each is one or two nucleotides selected from the group consisting of A, G, C, U and T, or a bond, X1 and X6, and X2 and X5 each form a Watson-Crick base pairs, and X3 and X4 are the same or different and each is a nucleotide selected from A, G, C, U and T.

Abstract: Methods for the fermentative production of four carbon alcohols is provided. Specifically, butanol, preferably isobutanol is produced by the fermentative growth of a recombinant bacterium expressing an isobutanol biosynthetic pathway.

Abstract: Compositions and methods for nitrogen sensitive regulation of expression of a transcribable nucleic acid molecule. One aspect provides a nitrogen-sensitive expression system that includes a transcription factor region comprising an NtcA binding site and a core promoter region comprising a RuBisCo promoter or a variant or a functional fragment thereof. Another aspect provides a method of transforming a host cell with an expression system. Also provided are expression cassettes, transformed host cells, and kits.

Abstract: The present invention provides methods for light-dependent gene regulation using a light-responsive DNA-binding protein. Also provided are related nucleic acid molecules, and protein molecules, such as those encoding or comprising the light-responsive DNA-binding protein or DNA-binding sites recognizing the light-responsive DNA-binding protein. Kits using the present light-dependent gene regulation system are further provided by the present invention.

Abstract: The present invention relates to recombinant microorganisms comprising biosynthetic pathways and methods of using said recombinant microorganisms to produce various beneficial metabolites. In various aspects of the invention, the recombinant microorganisms may further comprise one or more modifications resulting in the reduction or elimination of 3 keto-acid (e.g., acetolactate and 2-aceto-2-hydroxybutyrate) and/or aldehyde-derived by-products. In various embodiments described herein, the recombinant microorganisms may be microorganisms of the Saccharomyces Glade, Crabtree-negative yeast microorganisms, Crabtree-positive yeast microorganisms, post-WGD (whole genome duplication) yeast microorganisms, pre-WGD (whole genome duplication) yeast microorganisms, and non-fermenting yeast microorganisms.

Abstract: In one aspect, the invention relates to a transgenic bioluminescent plant including an expressible heterologous nucleotide sequence comprising a bacterial LUX operon, which includes LUX A, LUX B, LUX C, LUX D, LUX E, and LUX G genes, wherein the heterologous nucleotide sequence is expressed to render the plant bioluminescent.

Abstract: The invention provides compositions and methods related to selective inhibition of PPO11 and use for improving shelf life of a plant or parts thereof. In accordance with the invention, for example, compositions for topical application to a plant or part thereof, are provided that can reduce browning of the plant or part thereof to extend shelf life.

Abstract: This disclosure concerns compositions and methods for targeting peptides, polypeptides, and proteins to plastids of plastid-containing cells. In some embodiments, the disclosure concerns chloroplast transit peptides that may direct a polypeptide to a plastid, and nucleic acid molecules encoding the same. In some embodiments, the disclosure concerns methods for producing a transgenic plant material (e.g., a transgenic plant) comprising a chloroplast transit peptide, as well as plant materials produced by such methods, and plant commodity products produced therefrom.

Abstract: The present invention discloses gene targets and methods for the genetic control of lipid accumulation in vegetative (non-seed) portions of plants. Enhanced lipid, e.g. triacylglycerol (TAG), accumulation in vegetative portions of plants may be obtained by down-regulation of activity of At4g24160 or a homolog thereof. Plants, plant parts, seeds comprising down-regulated AT4G24160 activity, or activity of a homolog thereof, are also provided, as well as products prepared therefrom.

Abstract: Plant viral vectors have great potential in rapid production of proteins, but no simple Here a geminivirus-based system for high-yield and rapid production of oligomeric protein complexes, including virus-like particle (VLP) vaccines and monoclonal antibodies (mAbs) is described. In particular, a single vector that contains two non-competing replicons for transient expression in Nicotiana benthamiana leaves is described. The correct assembly of these subunit proteins into functional oligomeric structures (VLPs or full-size mAb) is also described. This system advances plant transient expression technology by eliminating the need for non-competing viruses, and thus, enhances the realistic commercial application of this technology for producing multiple-subunit protein complexes.

Abstract: This invention pertains to the discovery of mutant phytochromes that when introduced into a plant alter the photomorphogenic properties of that plant. In certain embodiments transfection of plants by nucleic acid constructs expressing the mutant phytochromes produced plants having a phenotype characterized by light-independent’ activation. Thus, in certain embodiments, this invention provides a transgenic plant or plant cell comprising a mutant phytochrome where the mutant phytochrome is a light-stable phytochrome; and the transgenic plant shows decreased shade avoidance as compared to the same species or strain of plant lacking the mutant phytochrome. In various embodiments the mutant phytochrome comprises a mutation at the position corresponding to tyrosine residue 276 in an Arabidopsis phytochrome where the mutation is to a residue other than tyrosine.

Abstract: Resistance of plants, particularly wheat and barley, to Fusarium head blight (FHB) and other Fusarium-related diseases may be induced or enhanced by transformation with a nucleic acid (DNA) construct comprising a nucleic acid sequence encoding the wheat ethylene-responsive transcription factor TaERF7-1 operatively linked to a promoter effective for expression in the plant. Plants transformed with the construct exhibit increased resistance to FHB and other Fusarium-related diseases in comparison to a non-transformed control plant. The transgenic plants may be produced from any plant, tissue or cell which is capable of regeneration, by transformation with the construct. Transformed plants, plant tissue or plant cells comprising the construct are selected, and the transgenic plant is generated therefrom.

Abstract: The present invention relates to recombinant DNA molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules in cell lines and organisms.

Abstract: Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2.

Abstract: Various embodiments of the present invention pertain to methods for biological production of hydrogen. More specifically, embodiments of the present invention pertain to a modular energy system and related methods for producing hydrogen using organic waste as a feed stock.

Abstract: A device comprising at least one electrode and at least one cell such as Anabaena variabilis cyanobacteria disposed on said electrode for producing ammonia. A layer of polymer, such as ion exchange polymer, can be used to help immobilize the cells. Whole cells or partially disrupted cells can be used. A method and a system for producing ammonia, comprising contacting at least one cyanobacteria such as Anabaena variabilis cyanobacteria with a media with an electrochemical perturbation is disclosed. The potential enhances ammonia production.

Abstract: Engineered microorganisms are provided that convert gaseous substrates, such as producer gas, into limonene. In some embodiments, limonene is pumped out of the cell via an efflux pump. In some embodiments, limonene, produced as described herein, is converted through catalytic dimerization into jet fuel. Producer gas used in the processes described herein for production of limonene may be derived from sources that include gasification of waste feedstock and/or biomass residue, waste gas from industrial processes, or natural gas, biogas, or landfill gas.

Abstract: The present invention provides host cells having improved sugar utilization or co-utilization, methods of producing host cells having improved sugar utilization or co-utilization, and methods of using host cells having improved sugar utilization or co-utilization. The present invention provides E. coli strains that co-utilize glucose and xylose in the presence of glucose and xylose, wherein the cell produces the product.

Abstract: The present invention provides isolated gene sequences involved in xylose fermentation and related recombinant yeast which are useful in methods of enhanced biofuel production, particularly ethanol production. Methods of bioengineering recombinant yeast useful for biofuel production are also provided.

Abstract: A microorganism capable of producing an acrylic acid (AA), wherein activities of a pathway producing AA through conversions of 3-HP to 3-HP-CoA and 3-HP-CoA to AA-CoA in the microorganisms are increased; as well as a method of producing the microorganism and a method of producing an acrylic acid by using the same.

Abstract: The present invention provides methods for producing a product of one or more enzymatic pathways. The pathways used in the methods of the invention involve one or more conversion steps such as, for example, an enzymatic conversion of guluronic acid into D-glucarate (Step 7); an enzymatic conversion of 5-ketogluconate (5-KGA) into L-Iduronic acid (Step 15); an enzymatic conversion of L-Iduronic acid into Idaric acid Step 7b); and an enzymatic conversion of 5-ketocluconate into 4,6-dihydroxy 2,5-diketo hexanoate (2,5-DDH) (Step 16). In some embodiments the methods of the invention produce 2,5-furandicarboxylic acid (FDCA) as a product. The methods include both enzymatic and chemical conversions as steps. Various pathways are also provided for converting glucose into 5-dehdyro-4-deoxy-glucarate (DDG), and for converting glucose into 2,5-furandicarboxylic acid (FDCA). The methods also involve the use of engineered enzymes that perform reactions with high specificity and efficiency.

Abstract: The disclosure provides a method for creating a transformant having significantly improved glucaric acid-producing capability and a method for efficiently producing glucaric acid using the transformant.

Abstract: The present invention is related to a recombinant microorganism for improved methionine production comprising modifications to produce methionine from glucose as main carbon source by fermentation, and modifications to improve glucose import, wherein the glucose import is improved by modifying the expression of at least one gene selected from ptsG, sgrT sgrS and dgsA. The invention is also related to a method for the fermentative production of methionine or methionine derivatives comprising the steps of: culturing the recombinant microorganism as described above in an appropriate culture medium comprising a fermentable source of carbon containing glucose and a source of sulphur, and recovering methionine or methionine derivatives from the culture medium.

Abstract: The present invention is related to a recombinant microorganism optimized for the fermentative production of methionine, wherein the activity of the cobalamin-independent methionine synthase MetE is attenuated in said microorganism. The invention is also related to a method for producing methionine by fermentation.

Abstract: A method for producing an L-amino acid is provided. An L-amino acid is produced by culturing a coryneform bacterium having an L-amino acid-producing ability, which is modified so that the activity of a phosphate transporter is increased, in a medium, and collecting the L-amino acid from the medium.

Abstract: Process for the enzymatic synthesis of the compound of formula (I): wherein R1 represents a hydrogen atom or an alkyl group. Application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid.

Abstract: The present invention relates to the field of biology, in particular to a sugar preparation method by using biomass sweet potato dregs for microbial fermentation as a sugar source. The liquid sugar product prepared with the method of the present invention essentially comprises the ingredient of glucose. The method of the present invention is of simple process, high specificity, good product quality and high yield, and solves the serious environmental pollution problem of the sweet potato dregs, thus having a good industrial application prospect.

Abstract: Disclosed are isolated nucleic acid molecules that have promoter activity specific to xylose. The synthetic promoters, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, promote the expression of a coding region of interest in transformed yeast cells.